Endurance training slows breast tumor growth in mice by suppressing Treg cells recruitment to tumors.
Animals
Cell Line, Tumor
Disease Progression
Endurance Training
Female
Forkhead Transcription Factors
/ metabolism
Kaplan-Meier Estimate
Lactic Acid
/ blood
Mammary Neoplasms, Experimental
/ immunology
Mice
Mice, Inbred BALB C
Mice, Nude
Physical Conditioning, Animal
Pilot Projects
Survival Rate
T-Lymphocytes, Cytotoxic
/ metabolism
T-Lymphocytes, Regulatory
/ metabolism
Tumor Burden
CD8+/FoxP3+ ratio
Endurance exercise
Forced running wheels
Hypoxia
Murine mammary tumor
Solid tumor progression
Treg cells
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
04 Jun 2019
04 Jun 2019
Historique:
received:
03
08
2018
accepted:
23
05
2019
entrez:
6
6
2019
pubmed:
6
6
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Aerobic exercise has been shown to slow tumor progression in rodents and humans, but the mechanisms behind this effect are still unclear. Here we show that aerobic exercise in the form of chronic endurance training suppresses tumor recruitment of FoxP3 Adult wild-type and athymic BALB/c female mice were endurance-trained for 8 weeks. Circulating leukocytes as well as muscle and liver mtDNA copy number were compared to aged-matched concurrent sedentary controls to establish systemic effects. 4 T1 murine mammary tumor cells were injected subcutaneously to the 4th mammary pad at the end of the training period. Tumor growth and survival rates were compared, together with antitumor immune response. Exercised wild-type had 17% slower growth rate, 24% longer survival, and 2-fold tumor-CD Cytotoxic T cells are a significant factor in endurance exercise-induced suppression of tumor growth. Endurance exercise enhances antitumor immune efficacy by increasing intratumoral CD8
Sections du résumé
BACKGROUND
BACKGROUND
Aerobic exercise has been shown to slow tumor progression in rodents and humans, but the mechanisms behind this effect are still unclear. Here we show that aerobic exercise in the form of chronic endurance training suppresses tumor recruitment of FoxP3
METHODS
METHODS
Adult wild-type and athymic BALB/c female mice were endurance-trained for 8 weeks. Circulating leukocytes as well as muscle and liver mtDNA copy number were compared to aged-matched concurrent sedentary controls to establish systemic effects. 4 T1 murine mammary tumor cells were injected subcutaneously to the 4th mammary pad at the end of the training period. Tumor growth and survival rates were compared, together with antitumor immune response.
RESULTS
RESULTS
Exercised wild-type had 17% slower growth rate, 24% longer survival, and 2-fold tumor-CD
CONCLUSIONS
CONCLUSIONS
Cytotoxic T cells are a significant factor in endurance exercise-induced suppression of tumor growth. Endurance exercise enhances antitumor immune efficacy by increasing intratumoral CD8
Identifiants
pubmed: 31164094
doi: 10.1186/s12885-019-5745-7
pii: 10.1186/s12885-019-5745-7
pmc: PMC6549262
doi:
Substances chimiques
Forkhead Transcription Factors
0
Foxp3 protein, mouse
0
Lactic Acid
33X04XA5AT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
536Subventions
Organisme : Indiana University Bloomington
ID : FRSP Seed Award
Références
J Immunol. 1999 Nov 15;163(10):5211-8
pubmed: 10553041
Physiol Rev. 2000 Jul;80(3):1055-81
pubmed: 10893431
Int J Biochem Cell Biol. 2005 Apr;37(4):822-34
pubmed: 15694841
CMAJ. 2006 Mar 14;174(6):801-9
pubmed: 16534088
Epidemiology. 2007 Jan;18(1):137-57
pubmed: 17130685
Exp Physiol. 2008 Jun;93(6):754-62
pubmed: 18281393
J Diabetes Sci Technol. 2007 Jul;1(4):558-69
pubmed: 19885119
Eur J Appl Physiol. 2010 Nov;110(5):925-32
pubmed: 20640439
Semin Oncol. 2010 Jun;37(3):297-302
pubmed: 20709211
J Appl Physiol (1985). 1990 May;68(5):1950-5
pubmed: 2141832
Breast Cancer Res. 2011 Apr 26;13(2):R47
pubmed: 21521526
Nature. 2011 Jul 13;475(7355):226-30
pubmed: 21753853
Cancer Res. 2012 May 1;72(9):2162-71
pubmed: 22549946
Exp Physiol. 2013 Jan;98(1):207-19
pubmed: 22613742
Mol Med Rep. 2012 Aug;6(2):426-8
pubmed: 22614633
Oncogene. 2015 Jan 29;34(5):546-57
pubmed: 24469056
Proc Biol Sci. 2014 Jul 7;281(1786):null
pubmed: 24850923
Braz J Med Biol Res. 2014 Oct;47(10):858-68
pubmed: 25140816
Cell. 2014 Nov 6;159(4):738-49
pubmed: 25417152
Nat Rev Immunol. 2015 Jun;15(6):335-49
pubmed: 25976513
Curr Protoc Mouse Biol. 2011 Mar 01;1(1):141-54
pubmed: 26068989
Sports Med. 2015 Oct;45(10):1469-81
pubmed: 26243014
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Gene. 2016 Jan 15;576(1 Pt 3):385-94
pubmed: 26526134
Curr Protoc Mouse Biol. 2015 Dec 02;5(4):283-290
pubmed: 26629772
J Sports Sci Med. 2015 Nov 24;14(4):747-55
pubmed: 26664271
Cell Metab. 2016 Mar 8;23(3):554-62
pubmed: 26895752
JAMA Intern Med. 2016 Jun 1;176(6):816-25
pubmed: 27183032
Clin Cancer Res. 2016 Oct 1;22(19):4766-4775
pubmed: 27407093
Vaccines (Basel). 2016 Aug 06;4(3):null
pubmed: 27509527
Oncotarget. 2016 Nov 15;7(46):75763-75773
pubmed: 27716621
Neurobiol Stress. 2016 Sep 09;5:8-18
pubmed: 27981192
Br J Sports Med. 2017 Apr;51(8):640-644
pubmed: 27993842
Prog Cardiovasc Dis. 2017 Jun - Jul;60(1):67-77
pubmed: 28385556
Front Immunol. 2017 Aug 02;8:829
pubmed: 28824608
Oncotarget. 2017 May 22;8(43):73947-73963
pubmed: 29088759
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097
BMC Immunol. 2018 Feb 17;19(1):9
pubmed: 29452585
Breast J. 2018 Sep;24(5):849-851
pubmed: 29517166
J Exp Med. 1980 Jan 1;151(1):69-80
pubmed: 6444236